Fate Therapeutics Inc (NASDAQ: FATE) stock enjoyed a major increase of 15.2% on 3/6/24. The shares closed at $7.98. Trading volume in this advance was normal. The stock has been exceptionally strong relative to the market over the last nine months and has risen 7.0% during the last week.
Current PriceTarget Research Rating
FATE is expected to be Value Creation neutral reflecting capital returns that are forecasted to be in line with the cost of capital.
Fate Therapeutics has a current Value Trend Rating of C (Neutral). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Fate Therapeutics has a poor Appreciation Score of 15 but a good Power Rating of 84, and the Neutral Value Trend Rating results.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment